Bahaa Bedair, MD
Pulmonary Disease · Saint Louis, MONPI 1356780449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 489 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 489 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Actelion Pharmaceuticals US, Inc.$740
- Insmed, Inc.$467
- Sanofi$395
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,235100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 143 | $2,209 |
| AstraZeneca | 87 | $1,573 |
| Boehringer Ingelheim | 46 | $1,054 |
| Actelion Pharmaceuticals US, Inc. | 32 | $740 |
| Insmed, Inc. | 22 | $467 |
| Sanofi | 19 | $395 |
| Regeneron Healthcare Solutions, Inc. | 17 | $388 |
| Amgen | 13 | $231 |
| Philips North America LLC | 10 | $198 |
| United Therapeutics Corporation | 9 | $178 |
| Merck | 8 | $171 |
| Grifols USA, LLC | 9 | $171 |
| Harmony Biosciences LLC | 5 | $165 |
| Tactile Systems Technology Inc | 5 | $165 |
| Electromed, Inc. | 19 | $151 |
| Pulmonx Corporation | 2 | $145 |
| Pfizer | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $108 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Axsome Therapeutics, Inc. | 4 | $80 |
| AbbVie | 3 | $74 |
| Novartis | 3 | $71 |
| Bayer | 3 | $49 |
| Viatris Specialty LLC | 2 | $47 |
| Mylan Specialty L.p. | 2 | $42 |
| Advanced Respiratory, Inc | 2 | $38 |
| 3b Medical, Inc. | 1 | $32 |
| Fisher & Paykel Healthcare Inc | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Baxter Healthcare | 1 | $20 |
| Verona Pharma, Inc. | 1 | $19 |
| Ambu Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,279 in reported general payments places this provider in the 75th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 666 | $598,829 |
| OfevNintedanib Esylate | 45 | $576,720 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 218 | $207,200 |
| Dupixent PenDupilumab | 31 | $128,676 |
| Breo ElliptaFluticasone/Vilanterol | 137 | $87,607 |
| EliquisApixaban | 96 | $82,148 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $69,364 |
| Fasenra PenBenralizumab | 11 | $69,344 |
| NucalaMepolizumab | 13 | $48,693 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $41,697 |
| Spiriva RespimatTiotropium Bromide | 46 | $27,349 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 58 | $15,073 |
| DuleraMometasone/Formoterol | 19 | $8,949 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 293 | $8,403 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $7,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Arexvy | $2,209 | $823,9531,003 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,054 | $645,766152 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,573 | $214,955235 claims |
| PfizerEliquis | $114 | $82,14896 claims |
| MerckDulera | $171 | $8,94919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.